Efficacy and Safety of rhTPO's Prophylactic Treatment of CTIT in Patients With High Risk of Cardiac Injury

PHASE4RecruitingINTERVENTIONAL
Enrollment

165

Participants

Timeline

Start Date

June 6, 2022

Primary Completion Date

June 30, 2024

Study Completion Date

August 31, 2024

Conditions
Cancer Treatment Induced Thrombocytopenia
Interventions
DRUG

rhTPO

rhTPO 300U/kg/d QD, subcutaneous injection applied for 5 days per cycle, total 3 cycles. If the patient's platelet count showed a trend of continuous decline and/or was accompanied by the risk of bleeding during the treatment or after the completion of 5 doses of rhTPO, the investigator judged that rhTPO should be continued for treatment, and rhTPO could be administered subcutaneously at 300U/kg/ day for a maximum of 14 doses per cycle. Discontinue when the absolute platelet count increases by ≥50×10\^9/L or when the platelet count rises to ≥250×10\^9/L.

DRUG

Control

Non-rhTPO treatment

Trial Locations (15)

100021

RECRUITING

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

100122

RECRUITING

Beijing Chaoyang District Sanhuan Cancer Hospital, Beijing

100144

RECRUITING

Peking University Shougang Hospital, Beijing

100853

RECRUITING

Chinese PLA General Hospital, Beijing

110801

RECRUITING

Liaoning Cancer Hospital & Institute, Shenyang

116011

RECRUITING

The First Affiliated Hospital of Dalian Medical University, Dalian

226001

RECRUITING

Affiliated Tumor Hospital of Nantong University, Nanyang

246003

RECRUITING

Anqing Municipal Hospital, Anqing

300181

RECRUITING

Tianjin Medical University Cancer Institute and Hospital, Tianjin

430022

RECRUITING

Union Hospital Tongji Medical College, Huazhong University of Science and Technology, Wuhan

430030

NOT_YET_RECRUITING

Tongji Hospital Tongji Medical College of Huazhong University of Science & Technology, Wuhan

450003

RECRUITING

Henan Provincial People's Hospital, Zhengzhou

450008

RECRUITING

Henan Cancer Hospital, Zhengzhou

710065

RECRUITING

Shaanxi Provincial Cancer Hospital, Xi'an

050011

NOT_YET_RECRUITING

The Fourth Hospital of Hebei Medical University, Shijiazhuang

All Listed Sponsors
collaborator

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER

collaborator

Anqing Municipal Hospital

OTHER

collaborator

Henan Cancer Hospital

OTHER_GOV

collaborator

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER

collaborator

Peking University Shougang Hospital

OTHER

collaborator

Chinese PLA General Hospital

OTHER

collaborator

Liaoning Cancer Hospital & Institute

OTHER

collaborator

Tianjin Medical University Cancer Institute and Hospital

OTHER

collaborator

Henan Provincial People's Hospital

OTHER

collaborator

Shaanxi Provincial Cancer Hospital

OTHER

collaborator

Beijing Sanhuan Cancer Hospital

UNKNOWN

collaborator

Hebei Medical University Fourth Hospital

OTHER

collaborator

Tongji Hospital

OTHER

collaborator

The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China

OTHER

collaborator

Bethune Charitable Foundation

UNKNOWN

lead

The First Affiliated Hospital of Dalian Medical University

OTHER